Literature DB >> 12470139

Noncontiguous tumor recurrence of posterior uveal melanoma after transscleral local resection.

Jonathan W Kim1, Bertil E Damato, Paul Hiscott.   

Abstract

OBJECTIVE: To describe the clinical and histopathologic features of noncontiguous tumor recurrence after transscleral local resection of posterior uveal melanoma.
METHODS: Chart review was performed to identify patients with noncontiguous tumor recurrences from a series of 494 consecutive patients treated with transscleral local resection for uveal melanoma. The clinical and histopathologic features of noncontiguous tumor recurrences were studied.
RESULTS: Nine cases were identified, for an estimated incidence of 1.8%. The average diameter of the primary tumors was 16.1 mm (range, 9-22 mm) and the average thickness was 9.8 mm (range, 6-14 mm). Noncontiguous tumor recurrences were solitary in 7 cases and multiple in 2 cases, with an average diameter of 5.8 mm (range, 3.0-9.5 mm). Eight of the 9 patients developed tumor recurrences at multiple intraocular sites. With a mean follow-up of 82.1 months (range, 22-171 months), 7 patients had a final visual acuity of counting fingers or worse, and there were 3 deaths from metastatic disease.
CONCLUSIONS: Noncontiguous tumor recurrence after local resection appears to be related to intraocular dissemination from the primary tumor, either through the natural course of the disease or secondary to surgical manipulation. Eyes with large primary uveal melanomas developing noncontiguous tumor recurrence have a high risk of developing tumor spread to multiple intraocular sites, and aggressive treatment is warranted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12470139     DOI: 10.1001/archopht.120.12.1659

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  9 in total

1.  Recurrent choroidal melanoma after transscleral local resection with diffuse vitreous seeding.

Authors:  Pedro Gonzalez; Ewan G Kemp; Fiona Roberts
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-03       Impact factor: 3.117

2.  Recurrent melanoma arising from sclera.

Authors:  Hillary C Stiefel; Audra Miller; David J Wilson; Daniel M Albert
Journal:  Am J Ophthalmol Case Rep       Date:  2022-05-05

3.  Initial results of fractionated CyberKnife radiosurgery for uveal melanoma.

Authors:  Faruk Zorlu; Ugur Selek; Hayyam Kiratli
Journal:  J Neurooncol       Date:  2009-02-22       Impact factor: 4.130

4.  Exoresection via partial lamellar sclerouvectomy approach for uveal tumors: A successful performance by a novice surgeon.

Authors:  Rengin Aslihan Kurt; Kaan Gündüz
Journal:  Clin Ophthalmol       Date:  2010-02-02

5.  Exoresection and endoresection for uveal melanoma.

Authors:  Kaan Gündüz; Nikolaos E Bechrakis
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 6.  Partial lamellar sclerouvectomy surgery for anteriorly located uveal tumour resection: a 20-year experience.

Authors:  Ibadulla Mirzayev; Ahmet Kaan Gündüz; Aylin Okçu Heper
Journal:  Eye (Lond)       Date:  2021-05-03       Impact factor: 4.456

7.  Surgical Approach in Intraocular Tumors

Authors:  Ahmet Kaan Gündüz; Ibadulla Mirzayev
Journal:  Turk J Ophthalmol       Date:  2022-04-28

8.  Feasibility, Method and Early Outcome of Image-Guided Volumetric Modulated Arc Radiosurgery Followed by Resection for AJCC Stage IIA-IIIB High-Risk Large Intraocular Melanoma.

Authors:  Maja Guberina; Ekaterina Sokolenko; Nika Guberina; Sami Dalbah; Christoph Pöttgen; Wolfgang Lübcke; Frank Indenkämpen; Manfred Lachmuth; Dirk Flühs; Ying Chen; Christian Hoffmann; Cornelius Deuschl; Leyla Jabbarli; Miltiadis Fiorentzis; Andreas Foerster; Philipp Rating; Melanie Ebenau; Tobias Grunewald; Nikolaos Bechrakis; Martin Stuschke
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

9.  Clinicopathologic correlations in eyes enucleated after uveal melanoma resection with positive surgical margins.

Authors:  Yousuf Khalifa; Thomas M Aaberg; Thomas M Aaberg; Hans E Grossniklaus
Journal:  Indian J Ophthalmol       Date:  2007 Sep-Oct       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.